Monkeypox-induced immunity and failure of childhood smallpox vaccination to provide complete protection.
Following the U.S. monkeypox outbreak of 2003, blood specimens and clinical and epidemiologic data were collected from cases, defined by standard definition, and household contacts of cases to evaluate the role of preexisting (smallpox vaccine-derived) and acquired immunity in susceptibility to monkeypox disease and clinical outcomes. Orthopoxvirus-specific immunoglobulin G (IgG), IgM, CD4, CD8, and B-cell responses were measured at approximately 7 to 14 weeks and 1 year postexposure. Associations between immune responses, smallpox vaccination, and epidemiologic and clinical data were assessed. Participants were categorized into four groups: (i) vaccinated cases, (ii) unvaccinated cases, (iii) vaccinated contacts, and (iv) unvaccinated contacts. Cases, regardless of vaccination status, were positive for orthopoxvirus-specific IgM, IgG, CD4, CD8, and B-cell responses. Antiorthopoxvirus immune responses consistent with infection were observed in some contacts who did not develop monkeypox. Vaccinated contacts maintained low levels of antiorthopoxvirus IgG, CD4, and B-cell responses, with most lacking IgM or CD8 responses. Preexisting immunity, assessed by high antiorthopoxvirus IgG levels and childhood smallpox vaccination, was associated (in a nonsignificant manner) with mild disease. Vaccination failed to provide complete protection against human monkeypox. Previously vaccinated monkeypox cases manifested antiorthopoxvirus IgM and changes in antiorthopoxvirus IgG, CD4, CD8, or B-cell responses as markers of recent infection. Antiorthopoxvirus IgM and CD8 responses occurred most frequently in monkeypox cases (vaccinated and unvaccinated), with IgG, CD4, and memory B-cell responses indicative of vaccine-derived immunity. Immune markers provided evidence of asymptomatic infections in some vaccinated, as well as unvaccinated, individuals.
Karem
Kevin L
KL
Poxvirus Program, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Atlanta, Georgia, USA.
Reynolds
Mary
M
Hughes
Christine
C
Braden
Zach
Z
Nigam
Pragati
P
Crotty
Shane
S
Glidewell
John
J
Ahmed
Rafi
R
Amara
Rama
R
Damon
Inger K
IK
D000293:Adolescent; D000328:Adult; D000818:Animals; D002478:Cells, Cultured; D002648:Child; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D045908:Mpox, Monkeypox / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control*; D012720:Severity of Illness Index; D012899:Smallpox / Q000453:epidemiology / Q000276:immunology*; D012900:Smallpox Vaccine / Q000008:administration & dosage / Q000276:immunology*; D014481:United States
D012900:Smallpox Vaccine
Emerg Infect Dis. 2001 May-Jun;7(3):434-8
11384521
Emerg Infect Dis. 2007 Sep;13(9):1332-9
18252104
JAMA. 2003 Jun 25;289(24):3295-9
12824212
Nat Med. 2003 Sep;9(9):1131-7
12925846
J Clin Microbiol. 2003 Sep;41(9):4068-70
12958227
J Immunol. 2003 Nov 15;171(10):4969-73
14607890
N Engl J Med. 2004 Jan 22;350(4):342-50
14736926
J Virol. 2004 Apr;78(8):3811-6
15047796
J Immunol Methods. 2004 Mar;286(1-2):111-22
15087226
Emerg Infect Dis. 2004 Mar;10(3):426-31
15109408
J Infect Dis. 2004 Oct 1;190(7):1286-94
15346340
Trop Geogr Med. 1988 Apr;40(2):73-83
2841783
J Infect Dis. 1990 Mar;161(3):446-8
2155973
Proc Natl Acad Sci U S A. 2005 Jan 18;102(3):547-52
15647345
Clin Diagn Lab Immunol. 2005 Jul;12(7):867-72
16002637
Nat Med. 2005 Sep;11(9):1005-11
16086024
J Infect Dis. 2005 Oct 15;192(8):1362-71
16170753
J Gen Virol. 2005 Oct;86(Pt 10):2661-72
16186219
Arch Pediatr Adolesc Med. 2005 Nov;159(11):1022-5
16275790
Nat Med. 2006 May;12(5):495-6; author reply 496-7
16675987
J Infect Dis. 2006 Sep 15;194(6):773-80
16941343
J Infect Dis. 2002 Jun 1;185(11):1657-9
12023773